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The rickettsiae belong to a group of Gram-negative, arthropod-borne, 
obligate intracellular bacteria that cause a wide spectrum of disease, 
varying from mild and self-resolving to fatal infections.[1-4] With 
the enhancement of diagnostic methodologies, specifically the use 
of molecular techniques, and improved ecological surveillance, the 
importance of rickettsial infections as neglected emerging infectious 
diseases globally has come to the fore.[2-7] The rickettsiae are distributed 
globally and disease occurrence is associated with the distribution 
of arthropod vectors.[4] The latter include various species of ticks, 
lice, fleas, mites and mosquitoes.[4] There are currently three groups 
of diseases commonly identified as rickettsioses: (i) spotted fever 
group (SFG) and typhus group (TG) rickettsial infections; (ii) scrub 
typhus, associated with Orientia tsutsugamushi (formerly Rickettsia 
tsutsugamushi); and (iii) human ehrlichioses and anaplasmosis caused 
by pathogens in the family Anaplasmataceae.[3,4,8-10] Rickettsioses do 
not have any specific pathognomonic signs, but rather a range 
of generalised signs and symptoms that may include fever, rash, 
lymphadenopathy and headache.[11] These symptoms together with a 
history of an arthropod bite (usually a tick bite) 1 - 2 weeks before the 
development of illness, in the presence or absence of a notable eschar 
(or tache noire), are considered highly suggestive of the diagnosis of 
rickettsiosis.
Spotted fever rickettsiosis, usually referred to as tick bite fever 
(TBF), is common in southern Africa.[12-16] Seroprevalence studies 
have indicated up to 80% positivity in specific communities, while 
the disease is often reported in travellers to southern Africa.[17-19] 
There are two main Rickettsia species associated with TBF in South 
Africa (SA), namely R. africae and R. conorii, causing African TBF 
and Mediterranean spotted fever, respectively.[16,18,20,21] R. africae is 
reportedly transmitted by Amblyomma (or ‘bont’) tick species, A. 
variegatum and A. hebraeum, whereas R. conorii has been associated 
with the brown dog tick, Rhipicephalus sanguineus.[16-18,21] Single 
cases of TBF in SA associated with R. aeschlimannii (transmitted 
by R.  appendiculatus)[21] and R. mongolotimonae have also been 
repor ted. [12] The clinical presentation of TBF associated with these 
different rickettsiae is very similar, however, and identification of 
the aetiological agent is not required for patient management.[16,18,21]
The clinical syndrome of TBF is usually uneventful and resolves 
with antibiotics, but fatal cases have been reported in patients with 
and without comorbid features.[1,18] Deaths are often associated with 
delayed clinical recognition and antibiotic treatment. Although clinical 
suspicion and patient response to doxycycline or tetracycline treatment 
are often used to diagnose cases of TBF, specific laboratory testing for 
TBF can be an important tool to direct patient management, especially 
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in severe cases.[16,18,21] The differential diagnosis of TBF is vast, 
including Crimean-Congo haemorrhagic fever, meningococcaemia, 
rubella, measles, secondary syphilis, disseminated gonococcal disease, 
enterovirus or arbovirus infections, anthrax, brucellosis, cat scratch 
disease, leptospirosis, typhoid, immune complex vasculitis or drug 
reactions, and the value of laboratory investigation should therefore 
not be underestimated.[16]
There are several factors to consider in the laboratory diagnosis of 
TBF. Conventional testing includes the Weil-Felix test, an agglutination 
assay detecting rickettsial antibodies in patient blood.[22] This test is no 
longer recommended as it lacks greatly in sensitivity and specificity, 
but it is still practised in some routine laboratories.[16] The indirect 
immunofluorescence assay (IFA) is considered the gold standard 
for TBF diagnosis and is the test most commonly performed in 
routine diagnostic laboratories.[22] This form of testing is rapid and 
sensitive, but antibody cross-reactivity between Rickettsia species 
renders the test unsuitable for discerning the exact cause of the 
infection. Other proteobacterial antigens may also cross-react with 
rickettsial antigens, and this should be taken into consideration in 
the interpretation of results. Importantly, anti-rickettsial antibodies 
only develop after the first week of illness, and serological tests may 
therefore be uninformative during the acute and early stages of 
disease. Results need to be interpreted in the context of the patient’s 
clinical history, since negative findings may inadvertently misdirect the 
diagnosis.[22] IFA, based on microscopic observation, requires highly 
skilled laboratorians to interpret the reading of the assay. A highly 
sensitive and reproducible enzyme-linked immunosorbent assay 
(ELISA) for anti-rickettsia antibody detection is also commercially 
available, and allows for the differentiation of immunoglobulin G 
(IgG) and immunoglobulin M (IgM) antibodies.[22] ELISAs have 
been shown to be more sensitive than IFAs in detecting low-level 
antibodies, and are suitable for demonstrating rising antibody titres.[22] 
Molecular techniques are increasingly being used to detect rickettsial 
DNA in eschar swabs, skin biopsies or blood.[22,23] These tests are, 
however, not as commonly available as serological testing. Culturing 
of rickettsiae is also not routinely available, as it requires the use of 
biosafety level 3 facilities and in vivo techniques.[6] Other commercially 
available diagnostic tests include other agglutination assays, indirect 
haemagglutination, immunoperoxidase assay, complement fixation 
tests, Western immunoblotting and line probe assays.[22] These tests 
vary in diagnostic sensitivity and specificity. In general, there is a lack 
of standardisation across the different testing platforms and between 
laboratories offering these tests.[22]
Objectives
To report on the status quo of laboratory testing for TBF in SA and on 
the findings of an inter-laboratory comparison (ILC) for serological tests.
Methods
Study participants
Five pathology service providers (hereafter laboratories) known to 
offer TBF testing were requested to participate in this study. They 
included laboratories servicing both the private and state healthcare 
sectors in SA.
Questionnaire
The study comprised two parts. The first part involved a questionnaire 
provided electronically to the laboratories, in order to determine the 
TBF testing available. Participation was voluntary and a period of 2 
weeks was allowed for respondents to submit their answers. It was 
requested that senior, qualified staff complete the questionnaire. The 
self-administered questionnaire comprised 53 questions divided into 
five sections, requesting information on serological and molecular tests 
offered and technical details of the tests (available on request from the 
corresponding author). The quality assurance system applied was also 
interrogated. The data were subsequently captured and analysed in an 
Excel spreadsheet, version 2016 (Microsoft, USA).
Inter-laboratory comparison
The second part of the study was an ILC exercise to gauge the 
performance and agreement of serological results for TBF for a 
standardised clinical specimen panel. Laboratories indicated in the 
previously mentioned questionnaire whether they were willing to 
participate in an ILC exercise. Three of the five laboratories offering 
TBF testing agreed to take part. A single ILC panel was supplied to each 
laboratory and testing was performed through their routine protocols. 
Participating laboratories were requested to test the panel per routine 
protocol for TBF serological testing (for both anti-rickettsia IgG and 
IgM) and to report the results to the provider within 4 weeks of receipt.
The ILC testing panel comprised 10 human serum samples and was 
accompanied by a clinical and exposure scenario to guide interpretation 
of the results. The samples were derived from clinical material 
collected through previous research projects or clinical submissions 
to the Centre for Emerging Zoonotic and Parasitic Diseases, National 
Institute for Communicable Diseases. Ethical clearance for the use 
of the archival material was obtained prior to the study from the 
University of the Witwatersrand Human Research Ethics Committee 
(ref. no. M120667) (amended) and the University of Pretoria Human 
Research Ethics Committee (ref. no. 222/2017). The serum panel was 
characterised through repeat testing with four different commercially 
available assays for rickettsia IgG and IgM determination: Vircell IgG 
and IgM R. conorii IFA (Vircell, Spain), Vircell IgG and IgM R. conorii 
ELISA, Focus Diagnostics IgG and IgM SFG and TG IFA (Focus 
Diagnostics, USA), and Fuller Laboratories IgG and IgM SFG ELISA 
(Fuller Laboratories, USA). Testing was conducted four times (once 
per kit) without deviation from the manufacturers’ guidelines, and 
the selection of samples included in the panel was based on consensus 
results of all four testing platforms. Four of the 10 samples included 
in the panel tested rickettsia IgG-positive, and the remaining six were 
IgG-negative. All 10 samples tested negative for IgM across all assays 
used. Only specimens that gave consistent, non-equivocal results were 
selected. Selected sera were homogenised by brief vortex mixing and 
centrifuged, followed by aliquoting and storage at –20°C. A subset of 
aliquots was subjected to stability testing, following storage at 4°C and 
–20°C, at 2-week intervals (i.e. distribution date, mid-point and closing 
of the ILC).
The panel was numerically coded with no identifiers linking a sample 
to patient information or the original study for which the samples 
were collected. The ILC panels were handled and transported on ice 
and in accordance with international regulations for the transport of 
diagnostic samples. Accompanying documentation included handling 
(including safety), storage and testing instructions, as well as a 
standardised response form.
Results reported were summarised in an Excel spreadsheet, version 
2016. The agreement of results submitted by the participants with the 
expected result was calculated as a proportion of results consistent with 
the expected results. Likewise, the overall agreement of results for IgG 
and IgM, respectively, was calculated as the proportion of all results in 
agreement with the expected results.
Results
Questionnaire 
All participating laboratories were compliant with the 2-week 
questionnaire and 4-week ILC result submission deadlines.
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Responses to the questionnaire were received from all five 
participating laboratories, representing both the private and state 
sectors of the SA healthcare system. Serological testing for anti-
rickettsia IgG and IgM was offered by all the laboratories, with three 
of the laboratories indicating that they also offered polymerase chain 
reaction (PCR) tests. All laboratories offering rickettsia serology used 
commercially available IFA kits for IgG and IgM antibody detection. 
Four of the five laboratories used the Focus Diagnostics IFA kit and 
one used the Vircell IFA kit. All the serological tests were based on 
R. conorii antigens, although R. africae would also be detected owing 
to antigenic cross-reactivity. All respondents indicated that the 
commercial kits were subject to in-house validation for diagnostic 
use. Four of the five laboratories indicated that the rickettsial 
serological testing offered was accredited to international standards 
through the South African National Accreditation System. Three of 
the four accredited laboratories conducted routine proficiency testing 
through the Royal College of Pathologists of Australasia.
In addition to serology, three laboratories indicated that they also 
offered PCR to detect rickettsial DNA targets. Importantly, PCR 
testing was not available for state facilities. Of the three laboratories 
that offered PCR diagnostic assays, one used an in-house-developed 
method employing previously published primers, and the other two 
used a commercially available real-time PCR targeting the gltA gene of 
all Rickettsia species. The laboratory that employed in-house methods 
had two real-time PCRs available, one that targeted the gltA gene for 
SFG rickettsiae and another that targeted the gltA gene for TG group 
rickettsiae. Various sample types (including blood, and eschar biopsies 
and swabs) may be tested using the commercial kit, but only plasma 
or serum was recommended for the in-house methods. Two of the 
three laboratories that offered rickettsial PCR used in-house-validated 
methods. None of the laboratories employed external proficiency 
testing or used accredited PCR methods.
Inter-laboratory comparison
Three laboratories participated in the serology ILC. Laboratory 1 used 
the Vircell IgG and IgM R. conorii IFA kit, while laboratories 2 and 3 
used the Focus Diagnostics IgG and IgM IFA kit. The expected results 
(obtained using four different assays, described above) and the results 
obtained by the participants are summarised in Table 1. All participants 
reported using manufacturers’ suggested protocols for the tests.
Overall agreement of results of 83% for IgG and 77% for IgM was 
achieved. Laboratories 2 and 3 reported false-positive IgG results for 
sample 2018/01-003, while all three participants reported false-positive 
results for sample 2018/01-010. No false-negative results were reported. 
For IgM, only laboratory 3 reported full agreement with expected 
results. Laboratories 1 and 2 collectively reported seven false-positive 
results for IgM. Half of the IgM results reported by laboratory 1 were 
false positive.
All three laboratories offered interpretation of negative and positive 
results in accordance with the kit manufacturers’ recommendations. 
Importantly, this included wording that indicated that negative results 
do not exclude the diagnosis of TBF. Two of the laboratories indicated 
the importance of considering the testing of paired samples.
Discussion
TBF is a common disease in SA, and although diagnosis is often based 
on clinical presentation alone, laboratory confirmation is recommended 
to ensure that patient management is well directed. At the time of the 
present study, rickettsial serological testing was routinely available from 
five pathology providers in SA, of which three participated in the ILC 
exercise. Although the IFA is currently regarded as a gold-standard 
method for TBF diagnosis, the value of PCR testing on appropriate 
samples has been widely reported. Although not subject to ILC in this 
study, it was determined that PCR testing was available from three 
laboratories in SA. It was noteworthy that PCR-based testing was 
not available in state-operated facilities. In addition, only one of the 
laboratories recommended PCR as a supplement to serological testing 
in their interpretation of negative serological findings.
There was a good agreement of results for IgG testing across the 
panel, and participants interpreted these results in line with the 
recommendations of the commercial kit providers and knowledge 
regarding cross-reactivity among Rickettsia species, and the requirement 
Table 1. Inter-laboratory comparison of results for rickettsia IgG and IgM tests
Sample reference 
number
Expected 
IgG result
Participant IFA IgG results
Agreement of 
results for all 
participants, % 
Expected 
IgM result
Participant IFA IgM results
Agreement of 
results for all 
participants, %Lab 1* Lab 2† Lab 3† Lab 1* Lab 2† Lab 3†
2018/01-001 Neg Neg Neg Neg 100 Neg Pos Neg Neg 67
2018/01-002 Pos Pos Pos Pos 100 Neg Pos Neg Neg 67
2018/01-003 Neg Neg Pos Pos 33 Neg Neg Neg Neg 100
2018/01-004 Pos Pos Pos Pos 100 Neg Pos Neg Neg 67
2018/01-005 Neg Neg Neg Neg 100 Neg Neg Neg Neg 100
2018/01-006 Neg Neg Neg Neg 100 Neg Pos Neg Neg 67
2018/01-007 Pos Pos Pos Pos 100 Neg Neg Neg Neg 100
2018/01-008 Neg Neg Neg Neg 100 Neg Neg Pos Neg 67
2018/01-009 Pos Pos Pos Pos 100 Neg Pos Pos Neg 33
2018/01-010 Neg Pos Pos Pos 0 Neg Neg Neg Neg 100
Agreement 
of results per 
participant, %
- 90 80 80 83 - 50 80 100 77
IgG = immunoglobulin G; IgM = immunoglobulin M; IFA = immunofluorescence assay: Lab = laboratory; Neg = negative; Pos = positive.
*Vircell IgG or IgM IFA kit.
†Focus Diagnostics IgG and IgM IFA kit.
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of follow-up testing for confirmation. The latter is important in the 
light of known high seroprevalence indicated in previous studies in SA, 
in order to elucidate previous v. current infections. A deficiency of the 
ILC exercise was that the measured serological titres or optical densities 
were not included in reporting and laboratories were expected to 
report only their final interpretation of the results. The titred results 
could have been useful to investigate the calling of false-positive 
results, particularly for sample 2018/01-010. The latter sample tested 
consistently negative by the panel provider with the two kits used 
by the participants, and also with an additional two commercial kits 
available at the time of the study.
The agreement of IgM results was less encouraging, with one of the 
participants reporting false-positive results for half of the panel. This 
laboratory used the Vircell IgG/IgM kit, while the other two participants 
used the kit supplied by Focus Diagnostics. Importantly, the samples 
tested repeatedly negative in the hands of the panel provider before 
and after the ILC exercise, using the Vircell kit but also the additional 
three commercial kits for IgM detection. To our knowledge, only 
one comparative study looking at commercially available rickettsia 
IFA kits has been published, which focused on comparison of the 
Focus Diagnostic IgG IFA kit with the Fuller Laboratories IgG IFA 
kit, and reported 100% agreement between the two kits when results 
were dichotomised in accordance with manufacturers’ cut-offs.[24] 
Our ILC participants indicated no deviation in the test protocol as 
recommended by the manufacturer, and included the initial IgG pre-
absorbing step, which is a common reason for false positives with IgM 
serological assays. As IFA is a microscopy-based method, the required 
subjective interpretation of visual observation may offer an explanation 
for the false-positive results (for example, with the observation of 
background autofluorescence). This subjectivity is generally regarded 
as a disadvantage of IFA methodology. In response to the ILC 
results, the laboratory in question followed up on the reporting of 
false-positive IgM results and concluded that they had indeed been 
overcalling background fluorescence, and have adjusted their protocol 
and training of staff accordingly.
Interestingly, none of the participants considered the use of the 
commercial IgM ELISA assay, which offers the advantage of objective 
result interpretation. In addition, laboratory 2 reported two false-
positive results. The rate of false-positive IgM findings was worrying, 
as these would support the incorrect diagnosis of TBF and could 
detract from the appropriate management of cases. A limitation of this 
study was the non-availability of IgM-positive serum samples, and this 
deficiency should be addressed in future ILC exercises to offer a more 
comprehensive analysis of interlaboratory performance.
The availability of proficiency testing panels for rickettsia serology 
globally is very limited, and owing to species diversity, which varies 
geographically, available panels may not represent the species of concern 
in a given region or country. The continued measure of performance 
across laboratories using well-characterised, local population-derived 
clinical material is therefore encouraged.
Conclusions
Currently there is no standardisation of laboratory diagnosis of TBF in 
SA. The consequence is variable reliability of test results and possibly 
a devaluation of the role of laboratory confirmation of the disease. As 
commercial kits are used for serological diagnosis, the importance of 
local population-based validation to gain better understanding of test 
sensitivity and specificity in the SA context cannot be understated. 
Expanding the use of PCR could be an important contribution to 
investigation of suspected TBF cases, and again the use of validated 
methods subject to proficiency testing is encouraged.
To our knowledge, this is the first national ILC for rickettsia serology 
that has been conducted in SA. The value of continued ILC efforts 
for rickettsia serology, and also PCR, in SA is recognised and may 
contribute to the standardisation and improvement of the quality of 
laboratory investigations for TBF in the country.
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